Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
BPMC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$73.04 - $121.90
Previous CloseN/A
Volume168.58K
Average Volume (3M)1.16M
Market Cap
$5.17B
Enterprise Value$5.66B
Total Cash (Recent Filing)$47.24M
Total Debt (Recent Filing)$9.04M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 01, 2025EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding63,906,010
10 Day Avg. Volume1,441,533
30 Day Avg. Volume1,162,417
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.14
Price to Cash Flow (P/CF)-48.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.57
Enterprise Value/Ebitda-34.49
Forecast
1Y Price Target
$130.25Price Target Upside53.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBlueprint Medicines Corp reported another quarterly beat, with Ayvakit revenue surpassing estimates driven by continued strength in iSM.
Mergers And AcquisitionsThe company is seen as a prime and scarce M&A target with a strong pipeline and visibility to significant revenue growth.
Revenue GrowthManagement raised net product revenue guidance, implying higher expected revenues.
Bears Say
Q1 Performance ConcernsThere are concerns about Q1 EPS and competitor SM data, with expectations for more normal Q1 headwinds like insurance re-verification.
Revenue Guidance SkepticismThe updated revenue guidance appears conservative, suggesting potential growth plateau despite strong Q2 performance.
Safety ConcernsSafety remains a concern with bezuclastinib, especially the liver signal.
---
Ownership Overview
1.54% Insiders
40.62% Mutual Funds
0.15% Other Institutional Investors
39.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BPMC FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was $73.04 and its highest was $121.90 in the past 12 months.
What is Blueprint Medicines’s market cap?
Blueprint Medicines’s market cap is $5.17B.
When is Blueprint Medicines’s upcoming earnings report date?
Blueprint Medicines’s upcoming earnings report date is May 01, 2025 which is in 10 days.
How were Blueprint Medicines’s earnings last quarter?
Blueprint Medicines released its earnings results on Feb 13, 2025. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.704 by -$0.086.
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate is -0.47.
How many shares outstanding does Blueprint Medicines have?
Blueprint Medicines has 63,906,010 shares outstanding.
What happened to Blueprint Medicines’s price movement after its last earnings report?
Blueprint Medicines reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.704. Following the earnings report the stock price went down -8.082%.
Which hedge fund is a major shareholder of Blueprint Medicines?
Currently, no hedge funds are holding shares in BPMC
---
Blueprint Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$130.25 (53.80% Upside)
$130.25 (53.80% Upside)
Blogger Sentiment
Bullish
BPMC Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 84.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.40%
12-Months-Change
Fundamentals
Return on Equity
-31.26%
Trailing 12-Months
Asset Growth
12.44%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
---
BPMC Company Deck
---
BPMC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, with strong revenue growth and market expansion for AYVAKIT, successful international progress, promising development of BLU-808, and financial discipline. However, some challenges in Q1 2025 and a heavy reliance on the U.S. market were noted.Read More>---
BPMC Stock 12 Month Forecast
Average Price Target
$130.25
▲(53.80% Upside)
Technical Analysis
Alkermes
―
Sarepta Therapeutics
―
Axsome Therapeutics
―
BridgeBio Pharma
―
Revolution Medicines
―
Best Analysts Covering BPMC
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
+1.29%
reiterated a sell rating 12 months ago
Copying David Lebowitz's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +1.29% per trade.
---